Vasogen's Celacade Shown to Significantly Reduce Time in Hospital in Prime Heart Failure Target Population - New Data from the ACCLAIM Trial Presented at the Heart Failure Society of America Meeting - Preparations Underway for FDA Meeting to Discuss Plans for Regulatory Submission in U.S. -
VOL. Up and it's working through resistance at .68 .
Posted by Vinnie on :
anybody knows how far away these guys are from fda approval?
Posted by ABEX TRADER on :
Yeah,like a mile!
They just announced so imagine they are working oversea's first and just announced their findings so it will not be tomorrow,but it is based on hope they will get through the FDA in the future and that is why people are putting $$ in it IMHO.
I have monitored the trades since 1:45pm and it has been trading in a narrow range so I am hoping it will break over the 70's and go to $1 atleast.
RSI is still not topping so it should have some room to run.
It must have been repriced quickly so who ever is getting in is paying anywhere from .65 on up.
This is VASO,I think, and they have been around for yrs. and I hope it's just their time for another runup.
Posted by 4Tune4Me on :
In at .66 and holding...This is working on a retrace. This company is near it's 52 week low and lost momentum in July when their Phase III ACCLAIM drug didn't show positive results. They've regrouped nicely and discovered that it does significantly (32%) reduce hospital stays for chronic heart failure patients....translates into huge dollar savings for insurance companies, eh. I'm not liking the retrace, but do like the long term outlook.
Posted by 4Tune4Me on :
also...they need to get their minimum pps up to stay on Nasdaq...have some time to do it in and incentive to hit a $1.00... I likey
Posted by ABEX TRADER on :
They can draw that out almost forever as most cos. apply for extensions with the SEC.
Right now the hedgies are playing it for their little dollars.
The day of the news it ranup in a flash and I think most of the $$ came in after that.
None of the lowpriced issues have been running which I hope changes in November as this is getting to be a real boring market to try to make a nickle in.
HAUP FCSE and a few others have made good gains since april,but I have not seen the runs we were seeing last year and with the market gettiing close to their highs thingss are going to slow down to a crawl real soon unless sentiment rises ,especially for low pricd issue. If people see that most higher priced issues are through with their runs maybe tthey will start looking for value in these issues again.